Latest News and Press Releases
Want to stay updated on the latest news?
-
Positive clinical data advance development with MIN-101 in schizophrenia and MIN-117 in major depressive disorder Additional trials also planned with MIN-202 in insomnia disorder and major...
-
WALTHAM, Mass., July 28, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...